Cell Cycle & Cancer

Arnaud BESSON


DR2

Team members

  Researcher
  • Maëlle CARRAZ
  • Christine DOZIER
  Professor
  • Anastassia HATZOGLOU
  Technical staff
  • Raphaël CULERRIER
  PhD
  • Justine CREFF
  • Ada NOWOSAD
  • Renaud PERCHEY

Presentation

Cyclin-dependent kinase (CDK) inhibitors (CKIs) of the Cip/Kip family are tumor suppressors by virtue of their ability to block cellular proliferation in the nucleus. However, increasing evidence indicate that CKIs also have cyclin-CDK independent functions that are potentially oncogenic. The main interest in the laboratory is to identify and characterize these novel functions and determine their importance in the context of tumorigenesis. The end goal is to use this knowledge to identify new prognostic markers and therapeutic targets or strategies for cancer diagnostic and treatment.

To study the cyclin-CDK independent functions of p27/Kip1 (p27) and p57/Kip2 (p57), we generated knock-in mouse models in which p27 or p57 can no longer bind to and regulate cyclin-CDK complexes. These animals provide a means to genetically dissect the functions of these proteins. In the lab, we combine the use of genetics with cellular, molecular and biochemical approaches to study the novel functions of these CDK inhibitors and their underlying mechanisms and to determine their importance in vivo, particularly in the context of tumorigenesis.

Cell cycle progression is driven by the activities of cyclin/cyclin-dependent kinase (CDK) complexes. One level of regulation of these complexes is provided by cyclin-CDK inhibitors (CKIs) which modulate their activity. The CKIs p27 and p57 are crucial regulators of the transition from G0, through G1, into S phase.

The importance of p27 in the control of cell proliferation is underscored by the phenotype of p27-null mice, which display a marked increase in body size and multi-organ hyperplasia. p27 is a tumor suppressor and mice lacking p27 are predisposed to both spontaneous and carcinogen induced tumorigenesis. In humans, p27 is a significant prognostic marker in many types of cancers and decreased levels of nuclear p27 are commonly observed in tumors.

On the other hand, p57 plays a prominent role during embryonic development and p57-null animals die around birth due to several developmental anomalies and this phenotype is reminiscent of the features observed in Beckwith-Wiedemann syndrome (BWS) in human. In fact, p57 is inactivated by mutation or silencing in most BWS cases.

 However, a more complex picture has recently emerged. Several lines of evidence indicate that p27’s role may not be limited to its tumor suppressive, cyclin-CDK inhibitor function. Unlike classical tumor suppressors, mutations of the p27 gene are exceedingly rare in tumors and p27 is preferentially inactivated by loss of nuclear p27 expression, either via increased proteolytic degradation and/or exclusion from the nucleus. In addition, in clinical studies, increased levels of p27 or its cytoplasmic localization in subsets of several types of high-grade tumors correlates with aggressive disease, poor prognosis and increased metastasis. Thus, evidence suggests that p27 has roles in the cytoplasm and may actively participate in the pathology of tumors. Indeed, Recent evidence indicate that p27 is involved in the regulation of various cellular processes, including cell migration and invasion, cytokseleton dynamics, transcriptional repression, autophagy, survival/apoptosis, and cytokinesis .

Increasing evidence also indicates that p57 has cyclin-CDK independent roles and other partners. Moreover, a fraction of Beckwith-Wiedemann syndrome cases originates from point mutations in p57 located outside of the cyclin-CDK regulatory region, suggesting that the loss of cyclin-CDK independent roles of p57 may, at least in part, be responsible for BWS. To this end we generated a p57CK- mutant mouse line in which p57 no longer binds to cyclins and CDKs to determine the importance of the cyclin-CDK independent roles of p57 in vivo, both in the context of BWS and tumorigenesis. This mouse model is currently being characterized.

Overall, our goal is to determine whether and how CDK inhibitors of the Cip/Kip family may act both as tumor suppressors and oncogenes depending on the cellular context. Our work also brings insight into fundamental aspects of biology, such as the regulation of cytokinesis or the mechanisms governing stem cell fate. We use a vast array of approaches ranging from the generation of novel murine models, biochemistry, and cellular and molecular biology. Our findings may help identify novel therapeutic targets to treat cancers.

 

Areas of interest in the lab include:

- To characterize the oncogenic roles of p27 in the cytoplasm, notably its relationship with Rho GTPases.

- To study the cyclin-CDK independent role of p27 during mitosis and cytokinesis, notably via the regulation of Citron Kinase.

- To investigate the cyclin-CDK independent functions of p57Kip2.

Immunostaining of β Tubulin (purple), Citron-Kinase (red) and DNA (blue) in mouse embryo fibroblast

Immunostaining of p57/Kip2 (red), β Catenin (green) and DNA (blue) in mouse intestinal epithelium

 

Publications

View all publications

Funding

     

Université Paul Sabatier
118 Route de Narbonne

31062 TOULOUSE Cedex
France

Annuaire général